Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
Primary Purpose
Cystinuria, Nephrolithiasis, Calcium Oxalate
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Cystone
Sugar Pill (Placebo)
Sponsored by
About this trial
This is an interventional treatment trial for Cystinuria focused on measuring Cystone, Uricare, Computerized tomography, Kidney calculi, Supersaturation, Nephrolithiasis, Quantitative CT
Eligibility Criteria
Inclusion Criteria:
- Written informed consent In the cystine arm, all patients will have the diagnosis of cystinuria, made on the basis of a 24-hour urine cystine containing more than 1500 umol of cystine, or a stone compositional analysis of cystine
- Presence of an existing cystine stone in one or both kidneys In the calcium arm, all patients will have a history of a calcium stone as determined by laboratory analysis.
- Medically effective birth control if fertile female
- Able to comply with protocol
Exclusion Criteria:
- Pregnant
- Subjects under age 18 years
- Obstructing stones
- Urinary Tract Infection that cannot be cleared with single course of antibiotic
- Subjects who decline to provide informed consent
Sites / Locations
- Mayo Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Placebo Comparator
Experimental
Arm Label
Cystone then sugar pill
Sugar pill then Cystone
Open-label Cystone
Arm Description
Subject will take Cystone for 6 weeks, then have a 1 week wash out period followed by the sugar pill for another 6 weeks
Subject will take sugar pill for 6 weeks, then a 1 week wash out followed by the Cystone for another 6 weeks
All subjects will receive Cystone for 46 weeks in the open-label period.
Outcomes
Primary Outcome Measures
24 Hour Urine Supersaturation of Calcium Oxalate (CaOx)
Urine is often supersaturated, which favors precipitation of crystalline phases such as calcium oxalate. However, crystals do not always form in supersaturated urine because supersaturation is balanced by crystallization inhibitors that are also present. Supersaturation is calculated by measuring the concentration of all the ions that can interact. Once these concentrations are known, a computer program can calculate the theoretical supersaturation with respect to the important crystalline phases, eg, calcium oxalate.
24 Hour Urine Supersaturation of Calcium Phosphate (Brushite)
Urine is often supersaturated, which favors precipitation of crystalline phases such as calcium oxalate. However, crystals do not always form in supersaturated urine because supersaturation is balanced by crystallization inhibitors that are also present. Supersaturation is calculated by measuring the concentration of all the ions that can interact. Once these concentrations are known, a computer program can calculate the theoretical supersaturation with respect to the important crystalline phases, eg, calcium oxalate.
24 Hour Urine Supersaturation of Calcium Phosphate (Hydroxyapatite)
Urine is often supersaturated, which favors precipitation of crystalline phases such as calcium oxalate. However, crystals do not always form in supersaturated urine because supersaturation is balanced by crystallization inhibitors that are also present. Supersaturation is calculated by measuring the concentration of all the ions that can interact. Once these concentrations are known, a computer program can calculate the theoretical supersaturation with respect to the important crystalline phases, eg, calcium oxalate.
24 Hour Urinary Cystine Excretion
Stone Density as Measured by Agatston Score Via Computerized Tomography
Agatston results are a measure of calcium typically used for measuring coronary artery calcification.
Volume of Kidney Stones as Measured on Computerized Tomography
Measurement of kidney stone volume in cubic millimeters.
Secondary Outcome Measures
Change in Stone Burden as Assessed by Radiologist at One Year
Stone burden will be quantitated using the stone quantification protocol currently available at Mayo that quantitates kidney stones both by volume and by density measured in Agatston units.
Full Information
NCT ID
NCT00381849
First Posted
September 27, 2006
Last Updated
January 4, 2016
Sponsor
Mayo Clinic
Collaborators
Himalaya Herbal Healthcare, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT00381849
Brief Title
Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
Official Title
Cystone for Treatment of Nephrolithiasis
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
April 2006 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
June 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
Collaborators
Himalaya Herbal Healthcare, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
We will investigate the safety and effectiveness of a mixture of 9 east Indian herbs known as Cystone regarding their ability to dissolve existing kidney stones and prevent formation of new ones. Cystine and calcium stone formers will be recruited for a 59 week trial. The first phase of the study will be two 6 weeks periods during which each subject will receive Cystone or placebo in random order (with a one-week wash out between 6 week treatment periods). The remaining 46 weeks, each subject will receive Cystone. End points are changes in urinary chemistries and stone burden by Computerized Tomography (CT) scanning.
Detailed Description
Cystone will be used in proven cystine and calcium stone forming adults who are not pregnant. Subjects must have a measurable stone by CT. The first phase is a double blind, randomized, placebo controlled cross-over of Cystone and placebo for 6 weeks each separated by a 1 week washout. Entry, 6 and 12 week 24 hour urine supersaturations or cystine, pH and sodium determinations will be collected. Then all patients enter an open label phase of 46 weeks, ensuring a 52-week total exposure to Cystone during the 59 week study. Baseline and 1 year stone quantification CT scans will be performed. End points will be changes in urine chemistry/supersaturation and stone burden. Stone burden was measured by CT, quantitatively for stone density and volume. All CT images were also reviewed in a blinded fashion by a radiologist to score each kidney as increased, no change or decreased stone burden.
Statistics and Randomization: Randomization was accomplished using a table provided by the department of statistics to the study coordinator who was blinded as to whether the patients received placebo or Cystone®. Biochemical and supersaturation results were analyzed via a matched pair analysis using the JMP software package (SAS Instituted, Inc.); P values < 0.05 were deemed significant.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystinuria, Nephrolithiasis, Calcium Oxalate
Keywords
Cystone, Uricare, Computerized tomography, Kidney calculi, Supersaturation, Nephrolithiasis, Quantitative CT
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cystone then sugar pill
Arm Type
Active Comparator
Arm Description
Subject will take Cystone for 6 weeks, then have a 1 week wash out period followed by the sugar pill for another 6 weeks
Arm Title
Sugar pill then Cystone
Arm Type
Placebo Comparator
Arm Description
Subject will take sugar pill for 6 weeks, then a 1 week wash out followed by the Cystone for another 6 weeks
Arm Title
Open-label Cystone
Arm Type
Experimental
Arm Description
All subjects will receive Cystone for 46 weeks in the open-label period.
Intervention Type
Drug
Intervention Name(s)
Cystone
Other Intervention Name(s)
Uricare
Intervention Description
Participants will take 2 pills, 2 times a day.
Each tablet of Cystone contains:
Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.
Intervention Type
Drug
Intervention Name(s)
Sugar Pill (Placebo)
Intervention Description
Participants will take 2 pills, 2 times a day for 6 weeks.
Primary Outcome Measure Information:
Title
24 Hour Urine Supersaturation of Calcium Oxalate (CaOx)
Description
Urine is often supersaturated, which favors precipitation of crystalline phases such as calcium oxalate. However, crystals do not always form in supersaturated urine because supersaturation is balanced by crystallization inhibitors that are also present. Supersaturation is calculated by measuring the concentration of all the ions that can interact. Once these concentrations are known, a computer program can calculate the theoretical supersaturation with respect to the important crystalline phases, eg, calcium oxalate.
Time Frame
baseline, after 6 weeks treatment on placebo, after 6 weeks treatment on cystone, at end of 46 weeks of open label cystone treatment
Title
24 Hour Urine Supersaturation of Calcium Phosphate (Brushite)
Description
Urine is often supersaturated, which favors precipitation of crystalline phases such as calcium oxalate. However, crystals do not always form in supersaturated urine because supersaturation is balanced by crystallization inhibitors that are also present. Supersaturation is calculated by measuring the concentration of all the ions that can interact. Once these concentrations are known, a computer program can calculate the theoretical supersaturation with respect to the important crystalline phases, eg, calcium oxalate.
Time Frame
baseline, after 6 weeks treatment on placebo, after 6 weeks treatment on cystone, at end of 46 weeks of open label cystone treatment
Title
24 Hour Urine Supersaturation of Calcium Phosphate (Hydroxyapatite)
Description
Urine is often supersaturated, which favors precipitation of crystalline phases such as calcium oxalate. However, crystals do not always form in supersaturated urine because supersaturation is balanced by crystallization inhibitors that are also present. Supersaturation is calculated by measuring the concentration of all the ions that can interact. Once these concentrations are known, a computer program can calculate the theoretical supersaturation with respect to the important crystalline phases, eg, calcium oxalate.
Time Frame
baseline, after 6 weeks treatment on placebo, after 6 weeks treatment on cystone, at end of 46 weeks of open label cystone treatment
Title
24 Hour Urinary Cystine Excretion
Time Frame
baseline, after 6 weeks treatment on placebo, after 6 weeks treatment on cystone, at end of 46 weeks of open label cystone treatment
Title
Stone Density as Measured by Agatston Score Via Computerized Tomography
Description
Agatston results are a measure of calcium typically used for measuring coronary artery calcification.
Time Frame
Baseline, approximately 52 weeks after baseline
Title
Volume of Kidney Stones as Measured on Computerized Tomography
Description
Measurement of kidney stone volume in cubic millimeters.
Time Frame
Baseline, approximately 52 weeks after baseline
Secondary Outcome Measure Information:
Title
Change in Stone Burden as Assessed by Radiologist at One Year
Description
Stone burden will be quantitated using the stone quantification protocol currently available at Mayo that quantitates kidney stones both by volume and by density measured in Agatston units.
Time Frame
Baseline, approximately 52 weeks after baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent In the cystine arm, all patients will have the diagnosis of cystinuria, made on the basis of a 24-hour urine cystine containing more than 1500 umol of cystine, or a stone compositional analysis of cystine
Presence of an existing cystine stone in one or both kidneys In the calcium arm, all patients will have a history of a calcium stone as determined by laboratory analysis.
Medically effective birth control if fertile female
Able to comply with protocol
Exclusion Criteria:
Pregnant
Subjects under age 18 years
Obstructing stones
Urinary Tract Infection that cannot be cleared with single course of antibiotic
Subjects who decline to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen B. Erickson, M.D.
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
21419606
Citation
Abdollahiasl A, Kebriaeezadeh A, Nikfar S, Farshchi A, Ghiasi G, Abdollahi M. Patterns of antibiotic consumption in Iran during 2000-2009. Int J Antimicrob Agents. 2011 May;37(5):489-90. doi: 10.1016/j.ijantimicag.2011.01.022. Epub 2011 Mar 17. No abstract available.
Results Reference
result
PubMed Identifier
21161651
Citation
Erickson SB, Vrtiska TJ, Canzanello VJ, Lieske JC. Cystone(R) for 1 year did not change urine chemistry or decrease stone burden in cystine stone formers. Urol Res. 2011 Jun;39(3):197-203. doi: 10.1007/s00240-010-0334-x. Epub 2010 Dec 16.
Results Reference
result
Links:
URL
http://clinicaltrials.mayo.edu
Description
Mayo Clinic Clinical Trials
Learn more about this trial
Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
We'll reach out to this number within 24 hrs